Articles on peptide science, backed by published research. New posts a few times a week.
Both drug classes carry consistent pregnancy language. The manufacturers' prescribing information states these medicines should not be used during pregnancy and should be discontinued when pregnancy is recognized. The stated rationale is twof
If you follow peptide research, you have probably noticed how often the same compounds show up in anti-doping headlines. Growth hormone secretagogues, IGF-1, EPO-adjacent agents, and a long tail of "research" peptides all sit somewhere on the World A
GLP-1 receptor agonists moved into adult obesity care first, but two of them now carry U.S. pediatric indications, and the trials behind those approvals are worth reading closely. This is a research log entry, not clinical guidance: the goal here is
Semaglutide entered public awareness as a glucose-lowering and weight-loss drug. The FLOW trial is the study that pushed it into a third arena entirely: kidney protection. For anyone keeping a research log on GLP-1 receptor agonists, FLOW is a landma
Tirzepatide is best known as the dual GIP/GLP-1 receptor agonist marketed for type 2 diabetes and for chronic weight management. But one of the most-discussed datasets around the molecule concerns a different organ entirely: the liver. In 2024, the *
Open almost any online peptide vendor and you will find the same two phrases repeated like a mantra: "Research Use Only" (RUO) and "Not for human consumption." It is easy to read them as a quality grade — as if "research use only" were a rung
GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide carry a cluster of upper-abdominal safety signals that get mentioned together and are easy to conflate: gallbladder
Most conversations about GLP-1 receptor agonists like semaglutide focus on the numbers on the scale. A quieter question sits underneath that headline: what happens to your skeleton when you lose weight quickly? Bone is metabo
Why does a research peptide ship in an insulated box with a cold pack? Why does the label say "store at -20°C," and why is a reconstituted vial good for weeks when the lyophilized powder lasts months? The answer is the same in every case: chemistry r
A little redness after a subcutaneous shot is one thing. A spreading rash, a swollen throat, and lightheadedness are a very different thing. Knowing which is which — before it happens — is one of the most practical safety skills anyone handling injec
Scroll through wellness content long enough and you'll meet "GLP-1 microdosing" — the idea that a small fraction of a standard semaglutide dose can deliver gentle weight loss, appetite control, "metabolic reset," or maintenan
A recurring idea in the longevity-peptide world is that a two-, three-, or four-amino-acid chain can be "assigned" to a single organ — one peptide for the brain, another for the pineal gland, another for cartilage — and that each one restores youthfu
Long before cagrilintide and amycretin made "amylin" a headline word in obesity research, one drug quietly proved the biology in humans: pramlintide, marketed as Symlin. It remains the only amylin-based medicine with full FDA approval, and it
Most of the incretin conversation centers on weight and glucose. Survodutide is interesting because its second target — the glucagon receptor — points somewhere else: the liver. This research log walks through what the published data actually show fo
For most of its public life, semaglutide has been discussed as a weight-loss drug. The SELECT trial is the study that complicated — and arguably rewrote — that framing. Published in the New England Journal of Medicine in De
One of the more striking storylines in metabolic medicine has nothing to do with weight. Patients on GLP-1 receptor agonists like semaglutide began reporting, unprompted, that they simply wanted to drink less. That anecdote h
The rationale rested on several converging threads. GLP-1 receptors are present in the brain, and GLP-1 signaling influences neuroinflammation, insulin signaling, synaptic plasticity, and cellular energy handling. Alzheimer's disease has been describ
Most of the GLP-1 receptor agonists that dominate headlines — semaglutide, tirzepatide — were developed in the United States or Europe. Ecnoglutide is a different story. Developed by Sciwind Biosciences, a metabolic-disease company headquartered in H
Pemvidutide (developer code ALT-801, from Altimmune) is an investigational, once-weekly injectable peptide being studied for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). It is described by its developer as a *balanced 1:1
VK2735 is an investigational drug candidate from Viking Therapeutics, developed as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Viking is pursuing it in two forms — a weekly s
A quick clarification before anything else, because it matters for how you file this one: tesofensine is not a peptide. It is a small-molecule drug, an oral compound, not an injectable peptide like the GLP-1 agonists it often gets compared to. We
Spend enough time in the peptide literature and a pattern starts to jump out: wildly different molecules — a metabolic drug, an appetite hormone, a compound studied for sexual desire — keep pointing at the same class of target. That targ
A recurring claim in peptide marketing is that a given compound "crosses the blood-brain barrier" and acts directly on the brain. It is worth slowing down on that phrase, because the blood-brain barrier (BBB) is one of the most selective interfaces i
When a peptide gets marketed as "clinically studied" or "in human trials," that claim is checkable. The U.S. National Institutes of Health runs a public registry, ClinicalTrials.gov, where sponsors register studies of drugs, devices, and biologics. A
One of the most persistent patterns in drug development is also one of the most humbling: a compound produces a clean, convincing result in mice, moves into human trials, and quietly disappears. This is not the exception. It is close to the rule. Und
When you read a peptide certificate of analysis, two numbers usually dominate the conversation: purity (that HPLC percentage everyone quotes) and the labeled milligram amount on the vial. But there is a third property that quietly changes what is act
Every peptide in a research catalog started as a chain assembled one amino acid at a time. Understanding how that chain is built explains a lot about the numbers you later see on a Certificate of Analysis (COA) — especially the purity percentage. T
Few research peptides carry as much hope — and as much room for over-claiming — as PNC-27. It is described in marketing copy as a peptide that "selectively destroys cancer cells," and the underlying laboratory story is genuinely interesting. But the
Most of the peptides in this research log come from metabolism, healing, or growth-factor biology. PE-22-28 is different: it comes from mood research, and specifically from a single, unusual drug target — the TREK-1 potassium channel. It is one of th
Few peptides sit at such an odd intersection of longevity folklore and genuine clinical curiosity as thymalin. It carries decades of published work behind it, a plausible biological rationale, and some genuinely striking mortality numbers — and y
Walk through the ingredient list of almost any "copper peptide" hair serum and you'll eventually run into two names: GHK-Cu and AHK-Cu. The first is well known and shows up everywhere in skin and hair formulations. The second is quieter, marketed alm
GLP-1 receptor agonists like semaglutide produce large, reliable reductions in body weight. But weight is not only fat. A recurring finding across trials is that some of the weight lost on GLP-1 therapy is lean mass — muscle
Semaglutide is the same molecule whether it arrives as a weekly injection or a daily tablet — but the delivery route changes almost everything about how much of it actually reaches the bloodstream, how it has to be taken, and how the numbers stack up
Amycretin is one of the more closely watched entries in the next wave of obesity and metabolic drug candidates. It is worth being precise about what it is and where it stands: as of mid-2026, amycretin is an investigational, early-stage molecule
Most of the GLP-1 conversation over the past few years has centered on injectable peptides. Orforglipron is a different kind of molecule, and that distinction is the whole point. This research-log entry tracks what the 2025-2026 Phase 3 readouts actu
Few experimental compounds capture the imagination quite like adipotide. The premise is striking: instead of suppressing appetite or nudging metabolism, adipotide was designed to attack the blood supply feeding fat tissue directly. In animal studies
SNAP-8 is one of those cosmetic ingredients that arrives pre-loaded with a marketing promise: a topical peptide that supposedly relaxes the muscles behind expression lines, the way botulinum toxin does — but from a cream, without a needle. It is a co
A quick honesty note before anything else: 5-Amino-1MQ is not a peptide. It is a small synthetic molecule — 5-amino-1-methylquinolinium, a quaternary ammonium salt built on a quinoline scaffold. It shows up in "peptide" catalogs and forums becaus
Vasoactive intestinal peptide (VIP) is one of those molecules that shows up in wildly different corners of the literature — gut physiology, lung medicine, immunology, and the contested world of chronic-illness "biotoxin" protocols. This research log
Most of the peptides catalogued in a research log come from the nuclear genome. Humanin is different: it is a small peptide encoded within mitochondrial DNA, and it has become one of the most-studied entries in an emerging class called *mitochondrial
Few molecules generate as much bodybuilding-forum excitement as follistatin, and few are as poorly served by that excitement. The underlying biology is real and well-characterized. The claim that you can buy a vial, inject it, and double your muscle
IGF-1 LR3 — short for Long R3 IGF-1 — is one of the more frequently searched entries in our peptide reference, and also one of the most misunderstood. It is an engineered analog of insulin-like growth factor 1 (IGF-1), desi
Cerebrolysin is one of the older entries in the neuropeptide world, and one of the most contested. It shows up in nootropic forums and clinic marketing as a "brain repair" agent, backed by a citation count in the hundreds. It also carries two facts t
Most peptides that circulate in wellness conversations are secretagogues, growth-factor fragments, or repair signals. Elamipretide is different in a way worth stating plainly at the outset: it is a clinical-stage drug with a defined molecular target,
Few molecules carry as much cultural baggage as oxytocin. Search the popular press and you'll find it called the "love hormone," the "cuddle chemical," the "trust molecule." Search the clinical literature and you find something more sober: one of the
Most of the melanocortin peptides discussed online live in a regulatory grey zone. Afamelanotide is the rare exception: it is an FDA-approved drug. But its story is unusually tangled, because the approved medicine and the "tanning peptide" sold in vi
Before the weekly injectables dominated headlines, there was liraglutide — the first GLP-1 receptor agonist to reach the metabolic mainstream as a genuine human GLP-1 analogue. It is easy, in 2026, to treat it as a footnote to semaglutide and tirzepa
Most osteoporosis drugs work by slowing down the loss of bone. Bisphosphonates, denosumab, and similar antiresorptive agents put the brakes on the cells that break bone down. Teriparatide did something different, and when the U.S. Food and Drug Admin
Most osteoporosis drugs work by slowing the breakdown of bone. A smaller group does the opposite: it tells the body to build new bone. Abaloparatide — sold as Tymlos — belongs to that second group. It is one of the better-d
The incretin therapy landscape is evolving at breakneck speed. While semaglutide and tirzepatide reshaped obesity treatment over the past few years, the next generation of multi-receptor agonists and combination therapies promises even greate
The peptide research landscape has shifted dramatically over the past two years. What was once a niche corner of biohacking forums has matured into a global self-experimentation movement, driven by increasing clinical validation, expanding gray-marke
The incretin-based therapeutic landscape has evolved rapidly over the past decade, moving from single GLP-1 receptor agonists to dual agonists like tirzepatide. Now, a new molecule is pushing the boundaries even further. Retatrutide (LY3437943),
Small fiber neuropathy (SFN) remains one of the most frustrating conditions in neurology — a disorder where standard nerve conduction studies come back normal, yet patients experience burning pain, autonomic dysfunction, and progressive loss of the t
Few peptides in the research landscape have generated as much sustained interest as BPC-157 (Body Protection Compound-157). First isolated from human gastric juice in the early 1990s, this 15-amino-acid peptide has accumulated a remarkable volume
The regulatory landscape surrounding compounded semaglutide and tirzepatide has shifted more times in the past two years than most researchers can track. What began as a straightforward drug shortage issue has evolved into a complex legal, sc
Obstructive sleep apnea (OSA) affects an estimated 936 million adults worldwide, and its prevalence is tightly coupled with the obesity epidemic. The standard of care — continuous positive airway pressure (CPAP) therapy — is effective but plagued
The SURMOUNT clinical trial program represents one of the most comprehensive evaluations of an anti-obesity medication ever conducted. Spanning multiple Phase 3 studies enrolling thousands of participants, this program established tirzepatide as
Every researcher who has stocked up on lyophilized peptides has faced the same nagging question: is this vial from eighteen months ago still viable? The answer is more nuanced than a printed expiration date suggests. Peptide stability depends on a co
The difference between 98% and 99% purity on a certificate of analysis might seem trivial — just one percentage point. But that single digit can represent a meaningful shift in impurity load, research reliability, and downstream biological effects. F
Cellular senescence — the state in which damaged cells permanently stop dividing but refuse to die — has emerged as one of the most compelling targets in aging research. These "zombie cells" accumulate with age, secreting a toxic cocktail of inflamma
The intersection of NAD+ biology and peptide science represents one of the more intriguing frontiers in longevity research. As our understanding of cellular energy metabolism deepens, researchers are exploring whether specific peptides can amplify or
The discovery of kisspeptin signaling in the early 2000s fundamentally reshaped our understanding of reproductive neuroendocrinology. Before kisspeptin was identified as the master upstream regulator of gonadotropin-releasing hormone (GnRH), research
The landscape of luteinizing hormone (LH) stimulation has shifted dramatically in recent years. With the FDA's crackdown on compounded human chorionic gonadotropin (HCG) beginning in 2020, researchers and clinicians have increasingly turned to **
The global peptide therapeutics landscape has been dominated by Western pharmaceutical giants for decades, with Novo Nordisk and Eli Lilly commanding headlines — and market share — with semaglutide and tirzepatide. But a seismic shift is unde
The research peptide market has exploded in recent years, driven by growing interest in compounds like BPC-157, TB-500, and various secretagogues. But this rapid growth has created a fragmented landscape where product quality varies enormousl
The idea that mitochondria communicate with the rest of the cell — and indeed the entire body — through secreted peptides has reshaped how researchers think about metabolism and aging. Among the most compelling of these mitochondrial-derived peptides
The discovery that mitochondria encode bioactive peptides has fundamentally shifted our understanding of cellular metabolism. Among these mitochondrial-derived peptides (MDPs), MOTS-c stands out as a particularly compelling molecule — one that ap
The next frontier in metabolic peptide research isn't a single molecule — it's a combination. CagriSema, a fixed-ratio co-formulation of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, has emerged from Novo Nordisk's pi
The practice of combining multiple peptides — often called "stacking" — has become widespread in the research and biohacking community. But most stacking protocols are built on anecdote rather than pharmacology. A mechanism-based approach asks a diff
The practice of combining multiple peptides into coordinated protocols — commonly known as "stacking" — has become increasingly prevalent among researchers and self-experimenters. The underlying logic is straightforward: if individual peptides target
The persistent redness, flushing, and inflammatory papules of rosacea affect an estimated 16 million Americans, yet the underlying pathophysiology remained poorly understood for decades. A breakthrough came when researchers identified a specific
The human body produces a remarkable arsenal of endogenous defense molecules, and few have attracted as much research attention as the sole cathelicidin-derived antimicrobial peptide found in humans. LL-37, a 37-amino acid peptide cleaved from th
Peptide researchers spend considerable time selecting the right sequences, optimizing storage conditions, and calculating precise dosing — yet the reconstitution medium is often an afterthought. The liquid used to dissolve a lyophilized peptide can p
Choosing the right solvent for peptide reconstitution is one of the most overlooked yet critical decisions in peptide research. Using the wrong diluent can degrade your compound within hours, compromise sterility, or introduce confounding variables i
While much of the metabolic drug landscape has centered on GLP-1 and GIP receptor agonism — exemplified by semaglutide and tirzepatide — Boehringer Ingelheim has pursued a fundamentally different combination. Survodutide (BI 456906) is a dual ago
The GLP-1 receptor agonist market has exploded into one of the most commercially significant pharmaceutical categories in history. Novo Nordisk's Wegovy and Ozempic generated over $21 billion in revenue in 2023 alone, while Eli Lilly's tirzepatid
The landscape of incretin-based therapies has evolved rapidly, moving from single-receptor agonists to dual and now triple agonists. Semaglutide, Tirzepatide, and Retatrutide represent three successive generations of this evolution, each
The idea that a single "smart drug" can universally enhance cognition is giving way to a more nuanced reality. Different cognitive demands—sustained attention, memory consolidation, anxiety regulation, even neuronal repair—recruit distinct neurochemi
Few peptides have generated as much intrigue — and controversy — in the nootropic community as Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide). Originally developed at Washington State University by Dr. Joseph Harding and colleagues, this hex
Peptide research has exploded in complexity over the past decade. With hundreds of synthetic peptides under active investigation — from BPC-157 and GHK-Cu to newer dual-agonists like tirzepatide — keeping track of protocols, biomarkers, a
The difference between reckless self-experimentation and meaningful personal research often comes down to one thing: documentation. In the world of peptide science, where individual responses vary dramatically and subtle effects unfold over weeks or
Growth hormone secretion and sleep are intimately linked through shared neuroendocrine pathways. MK-677 (ibutamoren), a non-peptide ghrelin receptor agonist that stimulates growth hormone (GH) release, has drawn significant research attention not
Growth hormone (GH) has long been a focal point of anti-aging research, body composition optimization, and recovery science. But exogenous GH injections are expensive, require refrigeration, and carry well-documented risks of supraphysiological dosin
Traveling with research peptides introduces a complex intersection of cold-chain logistics, aviation security regulations, and international customs law. Whether transporting reconstituted samples to a collaborator's lab or carrying lyophilized pepti
Research peptides occupy a unique space in experimental science — they're potent, sequence-specific signaling molecules that demand respect in handling, preparation, and administration. Yet the growing accessibility of synthetic peptides has outpaced
The peptide landscape has shifted dramatically in the first half of 2025. A convergence of regulatory enforcement, new drug approvals, and evolving compounding pharmacy rules has reshaped how researchers, clinicians, and biohackers access and study b
The peptide therapeutics landscape has shifted dramatically over the past twelve months. From next-generation obesity drugs entering phase III trials to breakthrough results in longevity signaling and antimicrobial peptides, 2025 has delivered some o
Growth hormone secretagogues have become a focal point in peptide research, offering a more physiological approach to modulating the GH axis compared to exogenous growth hormone administration. Among the most widely studied are Sermorelin and **I
Growth hormone (GH) secretion declines progressively with age — a phenomenon often referred to as somatopause. By age 60, many adults produce less than half the GH they did at age 25, contributing to changes in body composition, sleep quality, sk
The weight regain problem following GLP-1 receptor agonist discontinuation has become one of the most discussed challenges in obesity research. After the landmark STEP 1 trial extension showed that participants regained approximately two-thirds of lo
The rapid adoption of GLP-1 receptor agonists for metabolic health has introduced a critical clinical concern: the loss of lean body mass during pharmacologically-driven weight loss. Research consistently shows that 25-40% of weight lost on drugs
The rapid adoption of GLP-1 receptor agonists for metabolic research has raised a critical question in the scientific community: how much of the weight lost on these compounds comes from fat, and how much comes from lean tissue? For researchers and b
The humble insulin syringe has become the de facto standard for subcutaneous peptide administration in research settings worldwide. This wasn't an accident — it's the result of practical advantages in precision, availability, and safety that make U-1
Precision matters in peptide research. Whether reconstituting lyophilized peptides or drawing microliter-level doses, the syringe you choose directly impacts accuracy, waste, and reproducibility. Insulin syringes are the most common tool for subcutan
Ulcerative colitis (UC) affects approximately 3 million adults in the United States alone, with incidence rates climbing steadily worldwide. Current treatment paradigms rely heavily on immunosuppressants, corticosteroids, and biologics — therapie
Alpha-melanocyte-stimulating hormone (α-MSH) has long been recognized as one of the body's most potent endogenous anti-inflammatory signals. But the full 13-amino-acid peptide presents challenges for therapeutic development — including receptor-media
The concept of "food noise" — the persistent, intrusive mental preoccupation with eating — has rapidly moved from patient anecdote to legitimate research target. For many individuals living with obesity, this constant background chatter about food do
The clinical success of tirzepatide hinges not just on its novel dual-agonist mechanism, but on a carefully designed dose escalation protocol that balances efficacy against tolerability. Understanding how and why the titration schedule was struct
Gradual dose escalation isn't just a suggestion with semaglutide — it's a carefully engineered protocol that directly impacts tolerability, efficacy, and long-term adherence. Whether studied in the context of type 2 diabetes or obesity, the clini
Few figures in peptide science carry as much intrigue — or controversy — as Professor Vladimir Khavinson. Over a career spanning more than four decades, the Russian gerontologist developed a class of short peptides he termed "bioregulators," clai
The search for interventions that address aging at its molecular roots has led researchers to investigate a class of short regulatory peptides known as bioregulators. Among the most studied is Epithalon (also spelled Epitalon), a synthetic tetrap
The peptide therapeutics market faces a persistent bottleneck: most peptides are destroyed in the gastrointestinal tract before they ever reach systemic circulation. Oral bioavailability for unformulated peptides typically sits below 1-2%, making
The promise of peptide-based therapeutics hinges not just on the molecule itself but on how effectively it reaches its target. A peptide with extraordinary binding affinity is worthless if it's degraded in the gut, blocked by the skin barrier, or cle
Hexarelin (examorelin) stands out among growth hormone-releasing peptides (GHRPs) for its remarkable potency. As a synthetic hexapeptide analog of ghrelin, it triggers robust GH release by binding the growth hormone secretagogue receptor (GHS-R1a
Growth hormone secretagogues (GHS) have been a subject of intense pharmacological interest since the discovery that synthetic peptides could stimulate pituitary GH release independent of growth hormone-releasing hormone (GHRH). Among this class, **he
The concept of post-cycle therapy (PCT) originated in the anabolic-androgenic steroid (AAS) community as a protocol to restore endogenous hormone production after exogenous suppression. As peptide use has expanded among researchers and biohackers, co
Dose strategy is one of the most debated — and least standardized — variables in peptide research. Whether working with growth hormone secretagogues, metabolic peptides, or tissue-repair compounds, investigators must decide between two fundamentally
Cycling protocols are one of the most debated topics in peptide research, yet surprisingly little standardized guidance exists. Unlike small-molecule pharmaceuticals with well-defined prescribing information, many research peptides lack consensus on
Few peptides in sleep science carry as enigmatic a reputation as Delta Sleep-Inducing Peptide (DSIP). First isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep, this nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Se
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide first isolated from the cerebral venous blood of rabbits during induced sleep in 1977. Identified by Schoenenberger and Monnier,
The black box warning on every GLP-1 receptor agonist label is hard to miss. It cautions about thyroid C-cell tumors observed in rodents and advises against use in patients with a personal or family history of medullary thyroid carcinoma (MTC). For r
Gastrointestinal side effects remain the most common reason people discontinue GLP-1 receptor agonist therapy. While semaglutide and tirzepatide have demonstrated remarkable efficacy in clinical trials, their tolerability profiles deserve car
The intersection of immunotherapy and peptide science has produced few molecules with as long a clinical track record as Thymosin Alpha-1 (Tα1). Originally isolated from thymic tissue by Allan Goldstein in the 1970s, this 28-amino-acid peptide ha
The thymus gland has long been recognized as a central organ of the adaptive immune system, yet its endocrine functions remained poorly understood until the 1970s. It was during this period that Thymosin Alpha-1 (Tα1) was first isolated from thym
In the unregulated world of research peptides and SARMs, third-party testing serves as the primary quality assurance mechanism available to researchers. Without FDA oversight of these compounds for human use, independent laboratory analysis becomes t
Peptide research depends entirely on the integrity of the compound being studied. A poorly synthesized or contaminated peptide doesn't just waste money — it introduces confounding variables that can invalidate months of experimental work. Unfortunate
In the research peptide market, third-party lab reports — commonly called Certificates of Analysis (CoAs) — are the single most important tool for verifying what's actually in a vial. Yet many researchers and biohackers glance at these documents with
Among the handful of synthetic peptides that have achieved full FDA regulatory approval, tesamorelin stands out as a landmark case study. Approved in 2010 under the brand name Egrifta®, tesamorelin became the first and only therapy specifical
Among the growing landscape of peptide therapeutics, tesamorelin holds a distinctive position as one of the few growth hormone-releasing hormone (GHRH) analogs to achieve full FDA approval. Marketed under the brand name Egrifta®, tesamorelin
Peptides are inherently fragile molecules. Their biological activity depends on precise three-dimensional folding, intact amino acid sequences, and the preservation of chemical bonds that are surprisingly vulnerable to heat, moisture, and oxidation.
Researchers who work with peptides quickly learn a frustrating reality: the moment you add bacteriostatic water to a lyophilized vial, a countdown begins. That stable, shelf-friendly powder transforms into a fragile molecule in solution, vulnerable t
The synthetic melanocortin peptide Melanotan II (MT-II) has attracted widespread interest for its ability to induce skin tanning without UV exposure. Originally developed at the University of Arizona in the 1990s as a potential photoprotective ag
The pursuit of skin pigmentation without ultraviolet exposure has driven decades of peptide research, beginning with work at the University of Arizona in the 1980s. Melanotan II (MT-II) emerged from that research as a synthetic analog of alpha-me
Endotoxins are lipopolysaccharide (LPS) molecules found in the outer membrane of gram-negative bacteria. Even after sterilization kills the bacteria themselves, these heat-stable molecular fragments persist — surviving autoclaving at 250°C and po
Peptide purity is about more than just sequence fidelity. While researchers often focus on peptide content and amino acid identity, one of the most critical — and frequently overlooked — aspects of quality assurance is heavy metal contamination testi
The nasal cavity offers something most drug delivery routes cannot: a direct pathway to the brain. For neuropeptides like Semax and Selank, this anatomical shortcut isn't just convenient — it's arguably essential to their pharmacological acti
The anxiolytic heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) has attracted considerable attention in nootropic and research communities for its dual anxiolytic and immunomodulatory properties. Developed at the Institute of Molecular Genetics
Among the growing catalog of synthetic peptides under investigation, two stand out for their unique origins and overlapping yet distinct neurocognitive profiles. Selank and Semax were both developed at the Institute of Molecular Genetics of t
The premise behind AOD-9604 is elegantly simple: take the fat-burning fragment of human growth hormone, discard everything else, and avoid the side effects that make exogenous HGH a regulatory and metabolic minefield. It's a compelling pitch — ta
The search for targeted fat-loss agents has long driven pharmaceutical research, and few peptides illustrate the promise — and complexity — of that pursuit quite like AOD-9604. This modified fragment of human growth hormone (hGH) was designed to
The metabolic drug pipeline has moved decisively beyond single-target GLP-1 receptor agonists. While tirzepatide proved that dual agonism could outperform mono-agonists, the next generation of candidates is pushing further — adding glucagon recep
Eli Lilly's triple agonist retatrutide (LY3437943) generated enormous excitement after Phase 2 data showed unprecedented weight loss of up to 24.2% at 48 weeks. Now the company has launched one of the most ambitious obesity and metabolic dise
The incretin-based obesity pharmacotherapy landscape has evolved rapidly — from single GLP-1 receptor agonists like semaglutide, to dual agonists like tirzepatide, and now to a triple-hormone approach that may redefine the upper boundary of pharmacol
Anyone who has administered subcutaneous or intramuscular injections for weeks or months knows the pull of habit — the same spot on the abdomen, the same angle, the same routine. It feels efficient. But beneath the skin, repeated needle trauma to the
Subcutaneous injection is the primary route of administration for most research peptides, from BPC-157 and thymosin beta-4 to semaglutide and tesamorelin. While much attention is paid to dosing protocols and reconstitution techniques,
Growth hormone-releasing peptide-2 has earned a reputation as one of the most potent synthetic secretagogues in peptide research. It reliably stimulates pulsatile GH release, boosts appetite through ghrelin-mimetic activity, and has attracted conside
Growth hormone releasing peptides (GHRPs) represent a class of synthetic hexapeptides that stimulate the anterior pituitary to release growth hormone (GH) through activation of the ghrelin receptor (GHS-R1a). Among the most widely studied members of
The journey of PT-141 (bremelanotide) from a failed tanning peptide to an FDA-approved treatment for hypoactive sexual desire disorder (HSDD) is one of the more unusual stories in pharmaceutical development. Originally derived from **Melanotan II
Sexual dysfunction remains one of the most undertreated conditions in medicine, particularly for women. While phosphodiesterase-5 inhibitors like sildenafil revolutionized treatment for erectile dysfunction by targeting vascular mechanisms, they offe
Peptide research protocols demand precision. Whether reconstituting lyophilized powders or measuring doses from multi-use vials, a single decimal error can mean a 10-fold difference in the amount delivered. One of the most common sources of confu
Accurate reconstitution and measurement represent the single most critical skill in peptide research. Unlike pharmaceutical tablets with pre-measured doses, lyophilized peptides require researchers to calculate concentrations, select appropriate syri
Peptides are inherently fragile molecules. Their biological activity depends on maintaining precise three-dimensional structures, and even minor degradation can render a research compound useless. Temperature is the single most controllable variable
Peptides are inherently fragile molecules. Their biological activity depends on precise three-dimensional structures that can be disrupted by something as simple as leaving a vial on a countertop for too long. Whether you're managing a research lab i
The surge of interest in GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) for skin regeneration, wound healing, and anti-aging research has brought an often-overlooked biochemical reality into sharper focus: copper and iron do not operate indep
The tripeptide glycyl-L-histidyl-L-lysine was first isolated from human plasma in 1973 by Dr. Loren Pickart, who observed that aged liver tissue exposed to this peptide began synthesizing proteins at rates comparable to younger tissue. When bound to
The SURMOUNT-1 trial didn't just meet expectations — it shattered them. When results were published in The New England Journal of Medicine in July 2022, the magnitude of weight loss achieved with tirzepatide in adults without diabetes forced th
The incretin-based therapy landscape has shifted dramatically with the emergence of two blockbuster peptides targeting overlapping but distinct receptor pathways. Semaglutide, a GLP-1 receptor agonist, and Tirzepatide, a dual GLP-1/GIP recept
Few topics in the peptide research community generate as much confusion as the distinction between CJC-1295 with DAC and CJC-1295 without DAC (often called Modified GRF 1-29). Despite sharing a name, these two peptides behave very differently in the
Growth hormone (GH) optimization remains one of the most actively researched areas in peptide science. Rather than relying on exogenous GH administration, researchers have increasingly explored compounds that stimulate the body's own pulsatile GH rel
High-Performance Liquid Chromatography (HPLC) is the gold standard analytical method for assessing peptide purity. When you receive a Certificate of Analysis (CoA) from a peptide supplier, the HPLC trace — that chart with peaks rising from a base
For anyone sourcing research peptides outside of pharmaceutical supply chains, third-party analytical testing is the single most important quality assurance tool available. Among independent testing services, Janoshik Analytical has become one of the
The FDA's drug shortage list has become one of the most consequential regulatory documents in modern pharmaceutical policy — particularly for semaglutide, the GLP-1 receptor agonist that has reshaped the landscape of obesity and diabetes treatmen
The pharmaceutical industry rarely offers such a clean case study in drug pricing strategy as the one presented by semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. Sold under two brand names — Ozempic for type 2 diabetes an
The glucagon-like peptide-1 (GLP-1) receptor agonist class has fundamentally reshaped obesity research over the past decade. Among these compounds, semaglutide has emerged as the most extensively studied, producing weight loss outcomes in clinica
Few peptide stacks have generated as much grassroots enthusiasm as the combination of BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). Across research communities and biohacker forums alike, the pairing is frequen
Among peptide research circles, few combinations generate as much discussion as the pairing of BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). Both peptides have independently demonstrated tissue-repair propertie
The debate over injection site selection for TB-500 (Thymosin Beta-4 fragment) has persisted in both research and biohacking communities for years. Unlike many peptides where subcutaneous administration in the abdominal fold is standard practice,
Thymosin Beta-4 (Tβ4) is a 43-amino acid peptide that plays a fundamental role in cellular processes ranging from actin polymerization to wound healing. Originally isolated from the thymus gland, this naturally occurring peptide has become one of the
Choosing the right needle gauge might seem like a minor detail, but for researchers and self-experimenters administering peptide injections regularly, it directly impacts injection comfort, dosing accuracy, and tissue health over time. Insulin syring
The route of administration can fundamentally alter how a peptide behaves in the body — affecting absorption kinetics, bioavailability, onset of action, and even side effect profiles. For researchers and self-administering biohackers alike, the choic
The question of whether to administer BPC-157 orally or by injection is one of the most debated topics in the peptide research community. Unlike most peptides, which are rapidly degraded by gastric acid and proteolytic enzymes, BPC-157 demonstrat
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, it
Even researchers who source high-purity peptides and store them correctly can unknowingly sabotage their experiments at a deceptively simple step: reconstitution. The instinct to use as little bacteriostatic water as possible — to create a "stronger"
Most research peptides arrive as lyophilized (freeze-dried) powders — fragile, lightweight cakes or puffs sitting at the bottom of small glass vials. Before they can be used in any experimental protocol, they must be reconstituted: dissolved back int
Anyone who has compared research protocols for different peptides has noticed a striking inconsistency: some peptides demand administration multiple times per day, while others require only a weekly injection. The reason comes down to one of the most
Peptides are among the most actively studied molecules in modern biomedical research, yet they remain widely misunderstood. Often confused with proteins, steroids, or even small-molecule drugs, peptides occupy a unique space in biochemistry — small e